Cyr61 from adipose‐derived stem cells promotes colorectal cancer metastasis and vasculogenic mimicry formation via integrin αVβ5. Issue 12 (1st June 2021) - Liang, Zhenxing
Abstract : Adipose‐derived stem cells (ADSCs) play a vital role in colorectal cancer (CRC) progression, but the mechanism remains largely unknown. Herein, we found that ADSCs isolated from CRC patients produced more cysteine‐rich 61 (Cyr61) than those from healthy donors, and the elevated serum Cyr61 levels were associated with advanced TNM stages. Moreover, serum Cyr61 displayed a better diagnostic value for CRC compared to carcinoembryonic antigen (CEA) and carbohydrate antigen (CA19‐9). Mechanistically, integrin αV β5 was identified as the functional receptor by which Cyr61 promotes CRC cell metastasis in vitro and in vivo by activating the αV β5 /FAK/NF‐κB signaling pathway. In addition, Cyr61 promotes vasculogenic mimicry (VM) formation, thereby promoting tumor growth and metastasis through a αV β5 /FAK/HIF‐1α/STAT3/MMP2 signaling cascade. Histologically, xenografts and clinical samples of CRC both exhibited VM, which was correlated with HIF‐1α and MMP2 activation. Notably, we demonstrated the synergistic effect of combined anti‐VM therapy (integrin αV β5 inhibitor) and anti‐VEGF therapy (bevacizumab) in patient‐derived xenograft models. Further investigation showed that CRC cell‐derived exosomal STAT3 promoted Cyr61 transcription in ADSCs. These findings indicate that Cyr61 derived from ADSCs plays a critical role in promoting CRC progression via integrin αV β5 and provides a novel antitumor strategy by targeting Cyr61/αV β5 . Abstract : Cysteine‐rich 61 (Cyr61) derived from adipose‐derived stem cells (ADSCs) promotes colorectal cancer (CRC) metastasis and vasculogenic mimicry via binding to the integrin αV β5 receptor and activating the FAK signaling pathway. In turn, CRC cell‐derived exosomal STAT3 and p‐STAT3 promote Cyr61 transcription in ADSCs. These findings suggest that targeting of Cyr61/αV β5 may serve as a novel antitumor strategy in patients with CRC.